PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.

Pulse Biosciences shares rise on first-in-human study showing its nsPFA tech cuts thyroid nodule size with strong safety and efficacy.

Pulse Biosciences ( NASDAQ:PLSE - Get Free Report ) was upgraded by stock analysts at StockNews.com to a "sell" rating in a research note issued on Thursday. NASDAQ:PLSE opened at $14.86 on Thursday. Pulse Biosciences has a twelve month low of $3.78 and a twelve month high of $17.05.

Pulse Biosciences ( NASDAQ:PLSE - Get Free Report ) was upgraded by equities research analysts at StockNews.com to a "sell" rating in a research report issued on Thursday. PLSE opened at $14.86 on Thursday. The firm has a market capitalization of $820.57 million, a P/E ratio of -18.35 and a ...

StockNews.com upgraded shares of Pulse Biosciences ( NASDAQ:PLSE - Free Report ) to a sell rating in a research report report published on Thursday morning. NASDAQ:PLSE opened at $11.01 on Thursday. Pulse Biosciences has a 12 month low of $3.78 and a 12 month high of $14.96.

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects PVH Corp. PVH to report quarterly earnings at $3.52 per share on revenue of $2.42 billion after the closing bell, according to data from ...